Roswell Park Comprehensive Cancer Center researchers found that an opioid-restricting protocol resulted in a 45% decrease in the amount of opioids prescribed, without any significant effect on patient recovery or satisfaction.
Researchers found that treatment with immune checkpoint inhibitors has led to a significant improvement in survival and response rates in advanced sarcomatoid renal cell carcinoma.
A study led by researchers at Yale Cancer Center, Stony Brook University and KDx Diagnostics, Inc., examined a new urine screening test that utilizes a novel Keratin 17 (K17) cancer biomarker, and revealed the test can detect the presence of new bladder cancer in patients with hematuria, or blood in the urine.
Results from the interventional PATHFINDER study evaluating Galleri, a multi-cancer early detection (MCED) blood test, show that the blood test can detect cancers before symptoms arise.
A phase II clinical trial evaluating a personalized cancer vaccine, AV-GBM-1, in patients with newly diagnosed glioblastoma, demonstrated a 42% reduction in risk of disease progression or death at 6.9 months.
The myCare-022-03 study demonstrated that the Cellworks Singulaä Therapy Response Index is strongly predictive of overall survival and disease-free survival for glioblastoma patients.
The Ibex Medical Analytics Galen platform has received Breakthrough Device Designation from FDA.
The Breast International Group, the European Organization for Research and Treatment of Cancer and the Alliance Foundation Trials groups are collaborating with Sanofi to initiate a pivotal trial of an oral selective estrogen receptor degrader (SERD) in the adjuvant setting.
As American life returns to a semblance of normalcy, it may be time for President Biden’s administration to prioritize building a national digital health infrastructure.
NCI needs more funding to increase its low success rate of NCI-funded grant applications, David A. Tuveson said in testimony before the House Committee on Appropriations.
